Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

The aim of the present study was to determine whether modifying the local bone environment with osteoprotegerin (OPG), the soluble decoy receptor for receptor activator of nuclear factor-kappaB (RANK) ligand, could affect tumor burden and survival in the 5T33MM murine model of multiple myeloma. Trea...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों:	Vanderkerken, K, De Leenheer, E, Shipman, C, Asosingh, K, Willems, A, Van Camp, B, Croucher, P
स्वरूप:	Journal article
भाषा:	English
प्रकाशित:	2003

समान संसाधन

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
द्वारा: Croucher, P, और अन्य
प्रकाशित: (2003)

Osteoprotegerin and the development of myeloma bone disease
द्वारा: Croucher, P, और अन्य
प्रकाशित: (2004)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
द्वारा: Croucher, P, और अन्य
प्रकाशित: (2001)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
द्वारा: De Leenheer, E, और अन्य
प्रकाशित: (2004)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
द्वारा: Croucher, P, और अन्य
प्रकाशित: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
द्वारा: Croucher, P, और अन्य
प्रकाशित: (2000)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
द्वारा: Shipman, C, और अन्य
प्रकाशित: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
द्वारा: Croucher, P, और अन्य
प्रकाशित: (2001)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
द्वारा: Croucher, P, और अन्य
प्रकाशित: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
द्वारा: Croucher, P, और अन्य
प्रकाशित: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
द्वारा: Shipman, C, और अन्य
प्रकाशित: (2000)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
द्वारा: De Leenheer, E, और अन्य
प्रकाशित: (2002)

Bisphosphonates and in vivo models of multiple myeloma - Reply
द्वारा: Shipman, C, और अन्य
प्रकाशित: (2001)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
द्वारा: Shipman, C, और अन्य
प्रकाशित: (2002)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
द्वारा: Shipman, C, और अन्य
प्रकाशित: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
द्वारा: Shipman, C, और अन्य
प्रकाशित: (2003)

Bisphosphonates--mechanisms of action in multiple myeloma.
द्वारा: Shipman, C, और अन्य
प्रकाशित: (2000)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
द्वारा: Shipman, C, और अन्य
प्रकाशित: (2002)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
द्वारा: Mueller, G, और अन्य
प्रकाशित: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
द्वारा: Mueller, G, और अन्य
प्रकाशित: (2004)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
द्वारा: Croucher, P, और अन्य
प्रकाशित: (2002)

Role of osteoprotegerin (OPG) in cancer.
द्वारा: Holen, I, और अन्य
प्रकाशित: (2006)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
द्वारा: Holen, I, और अन्य
प्रकाशित: (2002)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
द्वारा: Clive Henry Buckle, और अन्य
प्रकाशित: (2012-01-01)

Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma
द्वारा: Jerome T. Higgs, और अन्य
प्रकाशित: (2017-11-01)

Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma
द्वारा: Jo Caers, और अन्य
प्रकाशित: (2010-01-01)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
द्वारा: Holen, I, और अन्य
प्रकाशित: (2002)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
द्वारा: Liesbeth Bieghs, और अन्य
प्रकाशित: (2010-01-01)

The role of osteoprotegerin in breast and prostate cancer
द्वारा: Holen, I, और अन्य
प्रकाशित: (2002)

Pangasius djambal gelatin increases osteoprotegerin, decreases RANK and RANKL after tooth extraction in vivo
द्वारा: Fredy Mardiyantoro, और अन्य
प्रकाशित: (2023-12-01)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
द्वारा: Edwards, C, और अन्य
प्रकाशित: (2007)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
द्वारा: Eaton, C, और अन्य
प्रकाशित: (2004)

The iron chelator deferoxamine decreases myeloma cell survival
द्वारा: Feifei Yang, और अन्य
प्रकाशित: (2021-01-01)

Anti-tumour activity of bisphosphonates in human myeloma cells.
द्वारा: Shipman, C, और अन्य
प्रकाशित: (1998)

Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment
द्वारा: K. Sfiridaki, और अन्य
प्रकाशित: (2011-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
द्वारा: Locklin, R, और अन्य
प्रकाशित: (2005)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
द्वारा: Shipman, C, और अन्य
प्रकाशित: (1997)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
द्वारा: Shipman, C, और अन्य
प्रकाशित: (2000)

Meiosis decreases recombination load; Mitosis increases recombination load
द्वारा: Root Gorelick, और अन्य
प्रकाशित: (2018-05-01)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
द्वारा: Shipman, C, और अन्य
प्रकाशित: (1998)